Abstract

The main objective of this study was to explore the molecular targets and mechanisms of Callerya nitida Benth. var. hirsutissima Z. Wei in the treatment of endometrial cancer. The active components of Fengcheng Jixueteng and their corresponding gene targets and the gene targets corresponding to endometrial cancer diseases were screened out from relevant databases. On this basis, the protein-protein interaction network was constructed and the hub target was screened. Then we performed pathway enrichment analysis on targets and analyzed the binding energy of drugs and disease targets through molecular docking. Pathway enrichment analysis screened out pathways in cancer, phosphoinositide-3-kinase-protein kinase signaling pathway and other signaling pathways. The active ingredients such as butein, 3',4',7-trihydroxyflavone, isoformononetin, genistein, isoliquiritigenin play an important role in the targets like epidermal growth factor receptor, xanthine dehydrogenase, 17-beta-hydroxysteroid dehydrogenase 1, estrogen receptor 2 and carbonic anhydrase 12. Molecular docking results demonstrated that the active compounds of the drug such as butein, isoformononetin, genistein and isoliquiritigenin had good affinity with the disease targets such as 17-betahydroxysteroid dehydrogenase type 1, xanthine dehydrogenase and carbonic anhydrase 12 respectively (the binding energy was <-5 kJ/mol). The main active compounds of the Fengcheng Jixueteng can act on many disease targets. It participates in the regulation of multiple signaling pathways such as pathways in cancer and phosphoinositide-3-kinase/protein kinase signaling pathway to play an anti-endometrial cancer role.